Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermatology,” will be held in the Gatlin D-E room of the Rosen Shingle Creek Resort on Thursday, May 17, 2018, from 12:00-1:30 PM ET.

“JAK inhibitors appear to be quite versatile molecules when it comes to treating inflammatory skin diseases, which is exciting. The fact that we could fill a symposium with presentations discussing new observations about treatment with these drugs within the past year is very telling,” notes symposium moderator John E. Harris, MD, PhD, Associate Professor of Dermatology, University of Massachusetts Medical School.

The following abstracts are scheduled to be presented at the symposium:

• Tofacitinib for recalcitrant cutaneous dermatomyositis. Abeer Alsarheed, Cambridge, MA. Abstract #503
• CXCL9 drives morphea pathogenesis in mice. Druhmil Patel, Worcester, MA. Abstract #102
• Photosensitivity and heightened type I IFN responses in cutaneous lupus are driven by elevated interferon kappa. Mrinal Sarkar, Ann Arbor, MI. Abstract #072
• Tofacitinib leads to increased infections by downregulation of antiviral immune defense. Heike C. Hawerkamp, Dusseldorf, Germany. Abstract #1056
• RAGE mediates UVB-induced persistent DNA Damage Response (DDR) and resistance to apoptosis in human melanocytes. Lynn A. Cornelius, St. Louis, MO. Abstract #1215
• Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia. Jindapa Thummakriengkrai, Thammasat University, Thailand. Abstract #1311
• Efficacy of oral tofacitinib in the treatment of lichen planopilaris. Brigitte Sallee, MD, New York, NY. Abstract #491